Medicare to Cover Breakthrough Devices in Just 2 Months

Patients waiting for breakthrough medical devices just got incredible news: Medicare coverage that once took over a year could happen in just two months.

The FDA and Centers for Medicare & Medicaid Services announced a game-changing partnership Thursday that will slash red tape for innovative medical devices. Under the new RAPID pathway, Medicare coverage decisions will begin the same day a device gets FDA approval.

The change addresses a frustrating gap in healthcare innovation. Companies could spend years developing devices that pass FDA standards, only to wait another year or more for Medicare to approve coverage. Patients needing these breakthrough treatments faced agonizing delays, even after devices proved safe and effective.

"FDA may no longer be their biggest concern," said Grace Graham, the FDA's deputy commissioner, describing feedback from medical device innovators. Companies wanted both agencies working together from the start, ensuring clinical trials meet everyone's requirements at once.

The RAPID program targets Class III breakthrough devices addressing unmet needs for Medicare beneficiaries, plus certain moderate-risk Class II devices. About 40 devices currently qualify, with 20 more potentially eligible through an existing fast-track program.

Here's how it works: when a qualifying device receives FDA market authorization, CMS immediately issues a proposed national coverage determination. After a required 30-day public comment period, coverage could take effect as quickly as two months instead of a year or more.

The Ripple Effect

This partnership represents more than faster paperwork. It transforms how medical innovation reaches the 67 million Americans on Medicare, many facing serious health conditions with limited treatment options.

Device manufacturers will receive guidance earlier in development, helping them design trials that satisfy both agencies simultaneously. This coordination prevents the costly scenario where a device clears one hurdle only to stumble at the next.

CMS Administrator Dr. Mehmet Oz emphasized the collaborative approach: "FDA and CMS each play a critical role in getting new medical devices to patients, and they work most effectively when aligned sooner in that process."

The agencies will publish a detailed procedural notice in the Federal Register with a 60-day public comment period. The pathway takes effect when the final notice publishes, potentially within months.

For patients awaiting breakthrough cardiac devices, diabetes technologies, or other life-changing treatments, the message is clear: help is coming faster than ever before.